| EN

刘志博2023.png

刘志博

联系方式:zbliu@cpl.ac.cn


教育经历(按时间倒序)


2010-2014 英属哥伦比亚大学,化学,博士

2006-2010 南京大学,化学,学士

 

工作经历(按时间倒序)


2019-至今 北京大学化学与分子工程学院应用化学(放射化学)系,副系主任

2023-至今 北京大学化学与分子工程学院,教授

2016-2022 北京大学化学与分子工程学院,特聘研究员

2016-至今 北大-清华生命联合中心,中心研究员

2014-2016 美国国立卫生研究院,博士后研究员


研究简介


研究方向:

活体化学及其驱动的蛋白激活及药物释放;

罕见病的影像诊断探针及临床转化研究;

中子捕获治疗药物及其辐射生物学效应;

新型医用核素的生产工艺研究与临床应用。


研究成果:

针对放射性新药的研发瓶颈和我国医用核素、核药物长期依赖进口的现状,刘志博团队致力于放射性药物化学领域的应用基础研究,在核药物的构效关系、核药物驱动的活体化学及其健康效应等关键科学问题上取得了重要突破。以通讯作者身份在Nature, Nat Comm, ACS Cent Sci, JACS, Angew Chem等杂志发表论文30余篇。承担国家杰出青年基金、科技部重点研发计划(青年项目)等各类科研项目10余项。提出了“固体靶在线溶解”的医用核素制备新理念,立足自研设备实现了 Ac-225、Pb-212、Bi-213、Y-86 等紧缺医用核素的国内首次制备,研发了硼氨酸等多种放射性“1 类新药”,并在临床试验中取得了成功(Nat Comm, 2022; JNM, 2022; EJNMMI 2022; EJNMMI, 2021; Theranostics,2021)。


主要荣誉


2021, Best Preclinical Publication Award, the 9th World ADC Annual Meeting

2021, Ones-to-Watch, Society of Nuclear Medicine and Molecular Imaging

2020, 中国化学会青年化学奖

2019, 药明康德生命化学青年学者奖

2019, 北京大学青年教师教学基本功大赛一等奖

2018, Fairchild Award, 18th International Congress of Neutron Capture Therapy

2018, 北京大学绿叶生物青年科学家奖

2016, Distinguished Scientist Award, NIH-CSSA Committee

2015, Michael J. Welch Postdoctoral Award, Society of Nuclear Medicine and Molecular Imaging

2015, JNM Editor’s Choice Award, Society of Nuclear Medicine and Molecular Imaging

2015, Alavi-Mandell Award, Society of Nuclear Medicine and Molecular Imaging

2014, Edward Piers Memorial Award, Edward Piers Foundation

2014, Chinese Government Award for Outstanding Abroad Students, China Scholarship Council

2013, Young Investigator Award, 37th CASNMMI

2013, Boehringer Ingelheim Scholarship, Boehringer Ingelheim Foundation


代表性成果(包括论文,专 著、专利等,不超过10项


1.  Qinyang Wang#, Yupeng Wang#, Jingjin Ding, Chunhong Wang, Xuehan Zhou, Wenqing Gao, Huanwei Huang, Feng Shao*, Zhibo Liu*. A Bioorthogonal System Reveals Antitumour Immune Function of Pyroptosis. Nature, 2020, 579, 421–426.


2.  Zhibin Guo#, Hanyu Hong#, Yuedan Zheng, Ziyang Wang, Zexuan Ding, Qunfeng Fu, Zhibo Liu*. Radiotherapy-Induced Cleavage of Quaternary Ammonium Groups Activates Prodrugs in Tumors. Angew Chem Int Ed, 2022, doi: 10.1002/anie.202205014.


3.  Mengqi Chen, Chunhong Wang, Zexuan Ding, Hao Wang, Yu Wang, Zhibo Liu*. A Molecular Logic Gate for Developing “AND” Logic Probes and the Application in Hepatopathy Differentiation. ACS Cent Sci, 2022, 8, 837.


4.  Jiyuan Li#, Qi Sun#, Chuanjie Lu, Han Xiao, Zhibin Guo, Dongban Duan, Zizhu Zhang, Tong Liu, Zhibo Liu*. Boron Encapsulated In A Liposome Can Be Used for Combinational Neutron Capture Therapy. Nat. Commun., 2022, 13, 2143.


5.  Zexuan Ding, Zhibin Guo, Yuedan Zheng, Ziyang Wang, Qunfeng Fu, Zhibo Liu*. Radiotherapy Reduces N-Oxides for Prodrug Activation in Tumors. J. Am. Chem. Soc., 2022, doi.org/10.1021 /jacs.2c02521


6.  Chunhong Wang, Hanyu Hong, Mengqi Chen, Zexuan Ding, Yuchen Rui, Zi-Chen Li, Zhibo Liu*. Cationic Micelle as An In Vivo Catalyst for Tumor-Localized Cleavage Chemistry. Angew. Chem. Int. Ed., 2021, 60, 19750–19758.


7.  Dongban Duan, Hao Dong, Zhiyu Tu, Chunhong Wang, Qunfeng Fu, Junyi Chen, Hai-peng Zhong, Ping Du, Ling-Dong Sun, Zhibo Liu*. Desilylation Induced by Metal Fluoride Nanocrystals Enables Cleavage Chemistry In Vivo. J. Am. Chem. Soc., 2021, 143, 2250–2255.


8.  Qunfeng Fu, Hongyu Li, Dongban Duan, Changlun Wang, Huimin Ma, Zhibo Liu*. External Radiation–Induced Local Hydroxylation Enables Remote Release of Functional Molecules in Tumors, Angew. Chem. Int. Ed., 2020, 59, 21546-21552.


9.  Pu Zhang#, Mengxin Xu#, Jie Ding, Junyi Chen, Taiping Zhang, Li Huo*, Zhibo Liu*. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy. Eur. J. Nucl. Med. Mol. Imaging, 2022, 49, 1985-1996.


10.  Mengxin Xu#, Pu Zhang#, Jie Ding, Junyi Chen, Li Huo, Zhibo Liu*. Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy. J. Nucl. Med., 2021, doi: 10.2967/jnumed.121. 262533.